Patients with a particular form of lung cancer who received a COVID-19 vaccine lived longer than those who did not, researchers said in a new study.
Patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine within 100 days of starting immunotherapy drugs survived longer on average than patients who did not, researchers with the University of Florida and University of Texas said in the paper, which was published by Nature on Oct. 22.
“The implications are extraordinary—this could revolutionize the entire field of oncologic care,” Dr. Elias Sayour, a pediatric oncologist at the University of Florida, said in a statement. “We could design an even better nonspecific vaccine to mobilize and reset the immune response, in a way that could essentially be a universal, off-the-shelf cancer vaccine for all cancer patients.”…